Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $1.75M | $2.05M |
| Revenue growth | — | 16.7% |
| Gross profit | $360K | $605K |
| Gross margin | 20.6% | 29.6% |
| Operating income | -$5.68M | -$3.33M |
| Operating margin | -324.0% | -162.9% |
| Net income | -$5.55M | -$3.74M |
| Net margin | -316.8% | -182.8% |
| EPS (diluted) | -$1.16 | -$0.76 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$2.60M | -$1.92M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $1.78M | $1.03M |
| Total assets | $3.58M | $4.14M |
| Total liabilities | $2.08M | $4.16M |
| Shareholders' equity | $1.51M | -$19.2K |
| Retained earnings | -$29.5M | -$33.2M |
| Shares (wtd avg diluted) | 4.80M | 4.93M |
Every figure is extracted from 20/20 Biolabs, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.